Despite a difficult regulatory environment, several medtech companies recently debuted new products, the biggest story being transcatheter heart valves, says Citi Investment Research Director Amit Bhalla.
“From a theme perspective, companies in 2010 that had new product stories were scarce commodities and turned out to be winners, so valuation didn’t matter as much if a new product was coming to market and was able to gain market share or advance technology,” Bhalla said.
Edwards Lifesciences (EW) and Medtronic (MDT) are the largest players in the transcatheter heart valve space, Bhalla says, adding that he has a “buy” rating on Edwards.
“We think transcatheter heart valves are beneficial to the health care system. They not only lower hospital costs in treating patients with aortic stenosis, but they also improve patient outcomes,” Bhalla said. “Those are the two big criteria that I think the health care system wants to see with new products coming to the market.”
Lowe’s Companies (LOW) Emerges From Housing Market Crash with Repurchase Commitment Set to Benefit Patient Investors
February 21, 2013
Graco Inc. (NYSE:GGG) Offers Customers Value Proposition Based on Lower Costs and Higher Quality
June 22, 2016
Solar Energy Equipment Manufacturers Lower Costs
September 21, 2011
Recommended Reading – Google’s CFO Search: Why’d it take so long?
June 27, 2008
Recommended Reading – Why ‘say on pay’ won’t work, Fortune
November 16, 2009
